Davide Matino at BIC 2025: Phase 3 Data on Fitelparvovec for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Updated Ph3 data on gene therapy for haemophilia A with giroctocogene fitelparvovec (AAV6, 3e13 vg/kg in 74 participants), presented by Davide Matino at BIC meeting 2025:
~35% of participants maintained near-normal to normal FVIII activity (40–150%) at 2 years post-infusion
Durability data is impressive: sustained efficacy approaches three years of follow-up, demonstrating the transformative potential of this AAV6 approach
- Slow decline pattern:
– Year 1 mean: 51.7%
– Year 2 mean: 51.9% (stabilization)
– Year 3 mean: 40.7% (median: 38.0%)
Note: Only 8 participants had 3-year follow-up
- Sustained FVIII levels >5% in >80% of participants at 15 and at 24 months
- 98.3% reduction in treated bleeding episodes (4.08 → 0.07 ABR post-infusion)
- Transient FVIII activity >150% in nearly 50%, managed with low-dose prophylactic DOAC in 30%
- One participant developed a thrombotic event (history of thrombosis and risk factors)
- 2 participants resumed FVIII prophylaxis
Generally well-tolerated safety profile with manageable ALT elevations (ALT ↑ in 61%)
High rate of infusion-related reactions (75%), but no discontinuation of study drug administration
One case of new cancer at 35 months (oral SCC, not related to study drug); in total 2 malignancies reported
One case of FVIII inhibitor development (more to follow tomorrow!)
Despite these results, Pfizer has discontinued this program and terminated their collaboration with Sangamo Therapeutics in December 2024”
More from BIC 2025 featured in Hemostasis Today.
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals